AHCO

Rating neutralAI MemoPost-earnings T+3

AdaptHealth

As of 2026-08-07/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-07 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Diabetes divestiture and debt actions may simplify the portfolio • 2026-11-05

Base target: $6 / p=55% prob

Biggest risk

The earnings reset exposed material margin and cash-flow pressure: FY2026 Adjusted EBITDA guidance fell to $490 million-$520 million, free-cash-flow guidance to $80 million-$120 million, and Q2 included a $144.2 million goodwill write-down. The capitated transition and manufacturer pricing pressure may persist.

Invalidation

Break below $4 or thesis failure.

What would change my mind?

Strong organic growth, full-scale capitated contracts, portfolio simplification, digital engagement, and restructuring savings could support a cleaner core earnings profile. The $9.8571 median target in the packet implies upside, but the analyst target count is unavailable.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-07

Base target

p=55%

Bull target

p=20%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Guidance reset creates an immediate margin-repair test
Capitated scale, digital engagement, and cost actions could improve core economics
Strong organic growth, full-scale capitated contracts, portfolio simplification, digital engagement, and restructuring savings could support a cleaner core earnings profile.

BearKey bullets

FY2026 Adjusted EBITDA guidance was reduced from $680 million-$730 million to $490 million-$520 million, with specific pressure from the West Coast capitated contract and manufacturer pricing.
[#SEC-8K-2026-08-04]
Post-earnings analyst revisions and a clean Aug.

WatchKey bullets

Diabetes divestiture and debt actions may simplify the portfolio

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $6 (p=55%)

Target spread vs base: +37% / -32%

Scenario probabilities

Bull Target: $9 (p=20%)Base Target: $6 (p=55%)Bear Target: $4 (p=25%)

Commentary

Primary evidence is strong but directionally mixed. Q2 showed robust organic growth and strategic simplification, while the sharp guidance reduction, weaker EBITDA, negative year-to-date free cash flow, and goodwill write-down dominate the risk assessment. The current anchor is $6.045 as of 2026-08-06; a clean post-print price-reaction series and analyst revision set are unavailable, so this remains a cautious monitoring view.

As of 2026-08-07 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Guidance reset creates an immediate margin-repair test
Capitated scale, digital engagement, and cost actions could improve core economics

Scenarios

Bull Target (Scenario probability)

$9 / p=20% prob

Base Target (Scenario probability)

$6 / p=55% prob

Bear Target (Scenario probability)

$4 / p=25% prob

Analysis 2026-08-07 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-05
Diabetes divestiture and debt actions may simplify the portfolio
AdaptHealth agreed to sell Diabetes Health for $235 million in cash, redeemed its 6.125% senior notes, and is concentrating on Sleep, Respiratory, and Wellness at Home. Execution and closing proceeds remain the key tests. [#SEC-8K-2026-08-04]
Prob 70.00% • Move 10.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Guidance reset creates an immediate margin-repair test
2026-11-05
Q2 delivered 15.9% organic growth and 12.7% reported revenue growth, but Adjusted EBITDA fell 3.2% and management lowered FY2026 guidance because of capitated-contract transition costs, a manufacturer price increase, and portfolio actions. [#SEC-8K-2026-08-04]
Prob 60% • Move 8% • Priced-in 70%

Long-term Catalysts

Months to a year

Capitated scale, digital engagement, and cost actions could improve core economics
2027-08-07
The West Coast capitated partnership reached full scale, Humana OneHome coverage transitioned approximately 478,000 members, myAPP users exceeded 512,000, and restructuring is expected to generate $19 million in annualized savings. The upside depends on converting scale into improved margins and cash flow. [#SEC-8K-2026-08-04]
Prob 55% • Move 18% • Priced-in 35%

Risks

FY2026 Adjusted EBITDA guidance was reduced from $680 million-$730 million to $490 million-$520 million, with specific pressure from the West Coast capitated contract and manufacturer pricing. [#SEC-8K-2026-08-04]
Post-earnings analyst revisions and a clean Aug. 4 market-reaction attribution are unavailable in the packet; low coverage limits confidence in forward estimates.
Q2 net loss attributable to AdaptHealth was $145.3 million, largely reflecting a $144.2 million goodwill write-down. [#SEC-8K-2026-08-04]
The Diabetes Health divestiture, contract scaling, and cost restructuring could create execution, stranded-cost, or cash-conversion risk.
Year-to-date free cash flow was negative $48.4 million versus positive $73.3 million in the comparable period. [#SEC-8K-2026-08-04]

Peers

Symbol	Summary
ABT	Large diversified healthcare-equipment benchmark; useful for sector sentiment but not a close operating comparable to AdaptHealth's home-care services model.
BSX	Large medical-device benchmark with limited direct read-through to AdaptHealth's reimbursement- and service-heavy home medical equipment business.
EW	Healthcare-equipment sentiment reference, but its procedure-device exposure makes it a loose peer rather than a direct operating comp.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-07

Loading AI feed…

Symbol

Summary

ABT

Large diversified healthcare-equipment benchmark; useful for sector sentiment but not a close operating comparable to AdaptHealth's home-care services model.

BSX

Large medical-device benchmark with limited direct read-through to AdaptHealth's reimbursement- and service-heavy home medical equipment business.

Healthcare-equipment sentiment reference, but its procedure-device exposure makes it a loose peer rather than a direct operating comp.